🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsInternationalHas anyone dealt with japan glp-1 access? Page 5

Has anyone dealt with japan glp-1 access?

Dr.PeteFamMed Fri, Oct 18, 2024 at 5:49 PM 35 replies 1,913 viewsPage 5 of 7
stefan_berlin
Member
234
1,123
Oct 2024
Berlin, DE
Oct 20, 2024 at 6:23 PM#21

Adding the numbers, since they settle part of this. Keep the original post as written when you update it, and add the correction underneath. An edited-away mistake is invisible to the next person who makes it.

24 24NeuroNate, JessicaH_TX, KevinCompounds and 21 others
Reply Quote Save Share Report
RegAffairsDC
Member
678
3,456
May 2024
Washington, DC
Oct 21, 2024 at 3:15 AM#22

Following on from PharmHunterJen — and this may be the naive question:

Did your prescriber agree with that reading, and if not what was their objection?

Last edited: Oct 21, 2024 at 5:15 AM
23 23Dr.SportsMedIN, amy_econ_NJ, bbq_ray_KC and 20 others
Reply Quote Save Share Report
Dr.EM_Chicago
Member
567
2,567
May 2024
Chicago, IL
Oct 21, 2024 at 12:07 PM#23
stefan_berlin said:
Keep the original post as written when you update it, and add the correction underneath.

I read this differently from stefan_berlin, on substance rather than tone. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.

22 22Dr.ReproEndo, lucas_SP_BR, lisa_labSD and 19 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
gary_naperville
Member
245
1,123
Oct 2024
Naperville, IL
Oct 21, 2024 at 8:59 PM#24
stefan_berlin said:
Keep the original post as written when you update it, and add the correction underneath.

That is right for the common case. Whether it is right for the case being asked about depends on a detail that has not been given.

Last edited: Oct 21, 2024 at 11:59 PM
21 21PharmHunterJen, TomTeleRx, DoseLogDan and 18 others
Reply Quote Save Share Report
amy_econ_NJ
Member
567
2,567
May 2024
Princeton, NJ
Oct 22, 2024 at 5:52 AM#25
stefan_berlin said:
Keep the original post as written when you update it, and add the correction underneath.

Thank you — that is the clearest version of this I have read, and I have read a lot of them. Printing the relevant bit and taking it with me.

Last edited: Oct 22, 2024 at 8:52 AM
20 20NurseLeah_Nash, gary_naperville, sean_dublin and 17 others
Reply Quote Save Share Report

Similar Threads

EU EMA compounding guidance — 2026 regulatory update9 replies
UK NHS GLP-1 prescribing — NICE TA875 and access guide7 replies
Australian TGA scheduling changes — peptide access 20268 replies
Canadian GLP-1 coverage — provincial formulary comparison6 replies
Purchasing GLP-1 in Mexico — legality, quality, and safety concerns6 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register